Zelgen(SH:688266)2023-12-11 01:02Group 1: Investor Relations Activities - The report documents investor relations activities conducted by Suzhou Zejing Biopharmaceutical Co., Ltd., including analyst meetings and specific object research [2] - Various securities firms participated in the activities, including CICC, Huatai Securities, and others, indicating a broad interest from the investment community [2] Group 2: Collaboration with Yuan Da Liaoning - The company signed an exclusive market promotion service agreement with Yuan Da Liaoning for recombinant thrombin, with a total payment of up to RMB 400 million, including an upfront payment of RMB 260 million and a milestone payment of RMB 140 million after 12 months of commercial sales [5] - The exclusive promotion service period lasts for 10 years from the effective date of the agreement, with future sales revenue fully counted as company income [5] Group 3: Market Research and Partner Selection - The company conducted thorough market research before selecting Yuan Da Liaoning as the exclusive promoter, focusing on the need for expertise in surgical hemostatic products [6] - Yuan Da Liaoning has a strong sales team and extensive experience in the hemostatic product market, covering approximately 6,000 hospitals [6] Group 4: Future Pricing and Production Capacity - The pricing for recombinant thrombin will be discussed jointly with Yuan Da, considering efficacy, safety, and market conditions [7] - The company has established a commercial production workshop for recombinant thrombin, which can meet initial sales demands post-approval, with plans for capacity enhancement [7] Group 5: Regulatory Progress - The company submitted the application for recombinant thrombin's market approval in April 2022, with the application accepted in May 2022, and has completed necessary inspections and reviews [8] - The review process is progressing smoothly, with expectations for timely approval [8] Group 6: Product Advantages - Recombinant thrombin is produced using patented technology, offering higher biosafety and coagulation activity compared to traditional plasma-derived products [9] - The product is the only recombinant thrombin undergoing Phase III clinical trials in China, with advantages in specificity, hemostatic efficiency, and lower risks of immunogenicity and infection [9] Group 7: Research Progress in Other Areas - The company is advancing clinical trials for Jackinib tablets in autoimmune diseases, with ongoing Phase III trials for severe alopecia areata and moderate to severe atopic dermatitis [10] - Research on recombinant human thyroid-stimulating hormone is also progressing, with two Phase III studies underway [10]